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Abstract  
 
Background: This study investigated predictors of response to topical 
diphenylyclopropenone (DPCP) immunotherapy in patients with alopecia areata (AA). 
Objective: To identify predictors of response, or resistance, to treatment for AA 
through clinical observations and serum tests. Methods: 84 AA patients were treated with 
DPCP. Serum cytokine levels were measured in 33 AA patients pre- and post-treatment, and 
in 18 healthy controls, using ELISA assays. Results: 56.1% of patients responded to DPCP 
with satisfactory hair regrowth; the response rate was negatively correlated with hair loss 
extent. Before DPCP treatment, higher serum IFN-γ and IL-12 cytokine levels were observed 
in AA patients compared to healthy controls. Non-responders to DPCP had significantly 
elevated serum IL-4 pre-treatment (3.07 fold higher) and lower IL-12 levels compared with 
responders. After DPCP treatment, non-responders had persistently high IL-4, increased IL-12, 
negligible decrease in IFN-γ and decreased IL-10. Post-treatment DPCP responders exhibited 
significantly decreased IFN-γ and IL-12, and increased IL-4 and IL-10. Development of 
adverse side-effects was significantly associated with higher pre-treatment serum IgE levels. 
Limitations: a small number of subjects were evaluated. Conclusions: Potentially, elevated 
pre-treatment serum levels of IL-4 and IL-12 can be used as unfavorable and favorable 
predictors of DPCP therapeutic effect, respectively. In addition, pre-treatment elevated serum 
total IgE may predict increased risk for severe adverse side-effects to DPCP application. 
Whether serum cytokine expression levels can be used as predictors of response to other 
forms of treatment is unknown, but it may warrant investigation in the development of 
personalized treatments for AA. 
 
1. Introduction  
 Alopecia areata (AA) is a common non-scarring inflammatory hair disorder, typically 
characterized by sudden onset of hair loss in the form of round or oval patches with a clear 
margin. So far, the etiopathogenesis of AA is not fully understood.[1-6] Studies suggest that in 
AA pathogenesis, a disturbance of T helper cell type 1 (Th1) and type 2 (Th2) immune 
equilibrium can occur. Elevation of Th1 related cytokines in response to various factors may 
change the immunologic privilege of hair follicles, enhancing CD8+ T lymphocyte 
cytotoxicity and natural killer cell (NK) activity, subsequently inducing follicular cell 
apoptosis, which contributes to hair loss in AA.[1-3,6-8] Current AA treatment modalities 
mainly include topical and systemic corticosteroids, T cell inhibitors, and topical hair follicle 
growth stimulants.[9-11] Severe cases of AA can require long-term systemic corticosteroids or 
immunosuppressive agents, which are not as effective as in mild cases, and may have 
significant adverse side-effects.  
Squaric acid dibutylester and diphenylcyclopropenone (DPCP) have been used 
extensively as contact sensitizers for AA treatment.[12-17] DPCP is a non-mutagenic chemical 
substance with a high sensitization potency, which does not react with other contact allergens; 
therefore it is a common agent used internationally in sensitization treatment of extensive 
AA.[14-15, 17-18] DPCP treatment has been found to have an efficacy rate ranging from 5% to 
85%, with a relapse rate ranging from 10.6% to 68.9% in AA patients.[14-15,18-23]   
           Although DPCP is considered as a good option to treat extensive AA, not all patients 
respond. A predictive indicator of response to DPCP is highly desirable for efficient treatment 
provision and to limit negative patient experiences. In this study, we present our experience 
with DPCP treatment in patients with severe types of AA, as well as the results of clinical and 
laboratory data analysis to understand the mechanism of action, and to identify biomarkers 
that predict the effectiveness of, and tolerance to, DPCP through convenient serum tests. 
 2. Materials and Methods 
 
2.1 Clinical Data 
            
A total of 84 patients with AA were enrolled into DPCP treatment at the Hair Clinic, 
Department of Dermatology, First Affiliated Hospital of Sun Yat-sen University, in the years 
2009 to 2012. Detailed clinical data for these patients were recorded. Inclusion criteria 
included chronic AA (disease duration more than 12 months), lack of response to other 
treatments, and more than 25% scalp area affected. Cessation of any topical or systemic AA 
therapy for at least six weeks was required prior to the start of DPCP treatment. 50 of 84 
patients were observed via dermoscopy, all of which exhibited the dermoscopic criteria of AA. 
The characteristic dermoscopic signs presented in the hair loss area included visible hair 
follicle ostia, yellow dots, cadaverized hairs (black dots), exclamation mark hairs, short vellus 
hair and newly-grown short hairs. The other 34 AA patients were not observed via 
dermoscopy as dermoscopy was not available when the patients started their treatment (before 
the year 2010). In these patients, the diagnosis of AA was made mainly by history, clinical 
presentation, and examinations. Exclusion criteria included <25% scalp area affected, 
pregnancy, significant cardiovascular disease, or serious medical illness. Informed written 
consent was obtained from all patients. All the procedures in this study were approved by The 
Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (No. 200990) and 
conform to the principles of the Declaration of Helsinki. 
 
2.2 Therapeutic Regime  
 Diphenylyclopropenone (diphencyprone) in acetone, at serial dilutions of 0.001%, 
0.01%, 0.05%,  0.1%, 0.25%, 0.5%, 1.0%, and 2.0%, was used in ascending order to seek the 
optimal concentration in treating AA patients. At the first visit, each patient was sensitized 
with 2% DPCP on an area of 2 cm in diameter behind the ear. After 2 weeks, progressively 
higher concentrations were applied to half of the scalp at weekly intervals until an acceptable 
response was achieved; ranging from 0.001% to 2% according to each patient's response. The 
other half of the scalp was not treated and was used as an intra-control to identify hair growth 
responses specific to DPCP. Once hair growth was established on one side, the other side was 
also treated. Patients were instructed to avoid direct sun exposure and to wash DPCP out only 
at 48h after each application.  
 
2.3 Efficacy Evaluation 
 Response of patients was evaluated by global photography and dermoscopy with a 
non-contact polarized dermoscope (Dermlite, DL3 model, 3Gen US, USA). The area of hair 
loss in the patients was evaluated using the SALT score method.[24] Hair regrowth was 
evaluated by the MacDonald-Hull and Norris grading system, i.e., grade I, vellus hair; grade II, 
sparse pigmented terminal hair; grade III, terminal hair regrowth with patches of alopecia; 
grade IV, growth of terminal hair over all of the treated scalp area.[25] Responders were 
defined as having grade III and grade IV hair regrowth scores, and non-responders as having 
grade II and grade I hair regrowth scores as well as no hair regrowth within 6 months after 
starting treatment. Relapse after achievement of hair regrowth was defined as when new hair 
loss affected more than 25% of the hair re-growth observed during DPCP therapy. Data was 
collected including the duration of DPCP treatment, concentration that elicited a good 
response, presence and type of side-effects, and relapse after completing treatment. 
 
2.4 Laboratory Tests  
 Complete blood count, serum IgE levels, thyroid antibodies (thyroid globulin antibody, 
TG-AB; thyroid peroxidase antibodies, TPO-AB), thyroid gland function (T3, T4, TSH) and 
immunological laboratory tests such as autoantibodies (ANA, ds-DNA, AHA, AnuA, DNP) 
were monitored pre- and post-treatment using immunoblotting, a semi-quantitative latex slide 
test, and radial immunodiffusion assays (R&D Systems, Shanghai, China) according to 
manufacturers’ protocols. 
 
2.5 Cytokine Expression Analysis  
 Serum cytokine levels were measured in 21 patients in the responder group and 12 
patients in the non-responder group both pre- and post-treatment, and in 18 healthy controls, 
using ELISA assays (R&D Systems, Shanghai, China). Serum cytokine levels of interferon 
gamma (IFN-), interleukin (IL)-2, IL-4, IL-5, IL-10, IL-12, IL-17, IL-18, and IL-22 were 
measured.  
 
2.6 Statistical Analysis 
 All analyses were performed using the software programs SPSS 13.0 (SPSS Inc, 
Chicago, IL). One-way analysis of variance (ANOVA) tests were conducted for continuous 
variables with normal distribution (One-way ANOVA). Non-parametric tests were used to 
evaluate differences between continuous variables which did not conform to the normal 
distribution (Shapiro-Wilk W test). χ2 test was used to show differences between categorical 
variables. According to the type of quantitative data, paired t test or Wilcoxon matched-
samples signed rank sum test were respectively used to evaluate differences between 
continuous variables pre- and post-treatment. Statistical significance was set at P= 0.05. P-
values less than 0.05 were considered significant.  
 
3. Results 
 
3.1 Clinical Data 
 In this group of 84 patients there were 38 males and 46 females, where age at onset of 
therapy with DPCP ranged from 5 to 63 years (mean 27.1± 12.7 years), and duration of hair 
loss ranged from 0.2 to 25 years (mean 6.0± 5.4 years). The area of hair loss in these 84 
patients ranged 25-100% (mean 82.3%±25.0%), with 7 patients (8.3%) in Grade I (25–49% 
scalp involvement), 20 patients (23.8%) in Grade II (50–74% scalp involvement), 11 patients 
(13.1%) in Grade III (75–99% scalp involvement) and 46 patients (54.8%) in Grade IV as 
alopecia universalis (AT) and alopecia totalis (AU) affected subjects.  
 
3.2 Response to DPCP Therapy 
 A total of 57 patients received DPCP treatments for more than 6 months, with the time 
long enough to evaluate the response to DPCP treatment (Figure S1). Of these, 32 patients 
had satisfactory hair regrowth (responders), and the overall rate of response was 56.1% 
(32/57), in which, 75.0% (3/4) were Grade I (25–49% scalp involvement), 73.3% (11/15) 
were Grade II  (50–74% scalp involvement), 85.7% (6/7) were Grade III (75–99% scalp 
involvement) and 38.7% (12/31) were Grade IV (AT and AU). Statistical analysis showed a 
negative correlation existed between response rate and hair loss area (χ2=8.386, P=0.004), but  
no significant association was found between response to treatment and the final 
concentration of DPCP applied, duration of AA, age, gender, atopic history (personal history 
of any atopic symptoms), nail involvement and other clinical features (data not shown).  
   Patients were divided into four groups according to their therapeutic response, i.e., 
responders (32/84), non-responders (25/84), withdrawal due to severe side-effects (7/84) and 
voluntary withdrawal (20/84). The clinical and laboratory characteristics of the four treatment 
groups are presented (Table 1). In the responder group, 19 cases were in grade III and 13 
cases were in grade IV according to the MacDonald-Hull and Norris grading system,[22] 
therapeutic effect was seen as early as the 6th week to the 22nd week, with an average of 
10.6±4.4 weeks. Twenty-seven patients withdrew for varied reasons, such as being unable to 
attend the clinic for weekly therapy (14 cases) and non-responsiveness to DPCP (6 cases). In 
addition, therapy was discontinued in 7 patients due to severe side-effects including 
development of vitiligo in one patient and intolerance to DPCP presented as systemic contact 
dermatitis in 6 patients.  
 
3.3 Treatment Reaction and Side-Effects 
 About 93% of patients (78/84) experienced one or more side-effects during treatment. 
Local dermatitis of the scalp in the DPCP contact area was the common finding in most of 
patients (70/78, 89.7%). Local lymphadenopathy in the draining area was another common 
side-effect (38/78, 48.7%). Other side-effects included scalp hyperpigmentation (32/78, 
41.0%), systemic contact dermatitis (11/78, 14.1%), scalp hypopigmentation (4/78, 5.1%), 
hyperpyrexia (1/78, 1.3%) and vitiligo (1/78, 1.3%). Apart from vitiligo, hyperpyrexia and 
systemic contact dermatitis, these side-effects in 87.7% (71/78) patients resolved after topical 
corticosteroid application, or with the use of systemic antihistamines, or after stopping the 
treatment for one week, but they did not lead to discontinuation of therapy.  
 
3.4 Relapse 
            A relapse rate of 40.6% (13/32) was observed. Relapse happened 4 to 65 
weeks after establishment of hair regrowth and these patients were followed up for a 
period ranging from 9 to 40 months after stopping the treatment. Of these patients, 4 
progressed to AU, who started a new treatment program with DPCP therapy to achieve 
excellent responses again. The remaining 9 patients lost 25% to 50% of re-grown hair, 
who did not start a new treatment. There was no significant association between the 
final concentration of DPCP applied and the relapse rate. 
  
3.5 Dermoscopic Features 
 Dermoscopy was performed in 50 patients before and after DPCP treatment, including 
22 responders, 17 non-responders, 2 in the severe side-effects group, and 9 in the voluntary 
withdrawal group (Figure S2). The incidence of yellow dots, broken hairs, cadaverized hairs 
(black dots), and exclamation mark hairs before treatment were 54.0% (27/50), 62.0% (31/50), 
62.0% (31/50) and 30.0% (15/50), respectively (Table 2). The incidence of broken hairs was 
higher in the responder group (77.3%) than in the non-responder group (41.2%) (χ2=5.28, 
P=0.022). With treatment, the average time of disappearance of yellow dots, broken hairs, 
cadaverized hairs (black dots) and exclamation mark hairs in the responder group was 17.1, 
14.6, 12.2 and 9.1 weeks respectively, but no correlation was found with effectiveness of 
treatment. In the non-responder group, besides 3 cases, not all the typical dermoscopic signs 
of AA had disappeared in the same patient. 
 
3.6 Laboratory Tests 
          Prior to treatment, elevated serum levels of T3 and T4 were found in 10 patients and 1 
patient, respectively. Serum levels of TSH were found elevated in 3 patients, but decreased in 
1 patient. Autoantibodies to the thyroid gland, TG-Ab and TPO-Ab were found positive in 17 
and 9 patients, respectively. Percentages and cell counts of peripheral eosinophils were found 
increased in 7 and 2 patients, respectively. ANA was found positive in 8 patients and 
increased IgE levels presented in 19 patients (Table 1). Comparison of the laboratory data 
among the responder, non-responder, and withdrawal due to severe side-effects groups, 
revealed no significant difference except that pre-treatment serum IgE levels were 
significantly higher in the withdrawal due to severe side-effects group than in the responder 
group (χ2=6.68, P=0.010) and the non-responder group (χ2=5.80, P=0.016). No significant 
differences were observed between responder and non-responder groups.  Elevated IgE levels 
also revealed no significant difference between the patients with and without atopic history. 
 
3.7 Cytokine Profiles 
Serum cytokine levels were measured in 21 patients in the responder group and 12 
patients in the non-responder group, both pre- and post-treatment, who completed treatments 
for more than 6 months, with the time long enough to evaluate the response to DPCP 
treatment, and also in 18 healthy controls. Before DPCP treatment in all AA patients, serum 
levels of IFN-γ and IL-12 were higher while IL-5 was lower than that in the healthy control 
group. No statistical significance was found on comparison of IL-2, IL-4, IL-10, IL-17, IL-18 
and IL-22 levels of AA patients to the normal control group (data not shown for the latter two 
cytokines). AA patients were divided further into responder and non-responder groups 
according to their response to DPCP treatment. In the responder group, serum levels of IFN-γ, 
IL-12 were higher, and IL-5 was lower, than controls while IL-2, IL-4, IL-10 and IL-17 were 
similar to that of controls. In contrast, in the non-responder group, serum levels of IFN-γ, IL-4, 
IL-12 and IL-17 were higher while IL-5 was lower than normal controls (Figure 1). In direct 
comparison with the responder group, significantly higher IL-4 and lower IL-12 serum levels 
were found in the non-responder group pre-treatment (Figure 2). Interestingly, in DPCP non-
responders, the IL-4 level was 3.07 and 3.10 fold higher compared to responders and controls 
respectively, whereas the IL-12 level was 0.75 fold lower than that of responders.  
           After DPCP treatment, there was a marked decrease in serum IFN-γ, IL-12 and an 
increase in IL-5, IL-10 and IL-17 levels in all AA patients as a group. Among them, IFN-γ 
was restored to a level similar to healthy controls, but IL-12, IL-4, IL-5 and IL-17 were higher 
than normal controls. Although IL-10 was higher in controls than AA patients prior to 
treatment, after the treatment it was similar to that of controls. However, there was an 
interesting discrepancy in cytokine profiles between responder and non-responder groups. In 
the responder group, marked decreased serum IFN-γ and IL-12 levels were noted post-
treatment as compared to pre-treatment levels, and restored to the level of normal controls. 
However, increased IL-4, IL-5, IL-10 and IL-17 serum levels were found in responders post-
treatment when compared to pre-treatment levels as well as to controls.  
In contrast, in the non-responder group, the decrease in IFN-γ serum level was only 
mild, and no significant difference was found between pre- and post-treatment levels, both 
being higher than that in the control group. An increase in post-treatment serum IL-12 level 
was found as compared to pre-treatment, rather than a decrease as seen in the responder group. 
Increased IL-5 and IL-17 serum levels were found in the non-responder group when compared 
to pre-treatment levels as well as to controls. IL-4 level remained high, and no difference was 
noted in serum IL-4 and IL-10 pre- and post-treatment (Figure 1). When comparing between 
responder and non-responder groups after the treatment, higher IL-4, IL-12, IFN-γ and lower 
IL-10 serum levels were found in the non-responder group (Figure 2). 
 
4. Discussion 
The treatment of severe AA can still be a difficult task; development of new and 
improved treatments for extensive AA is an area of active investigation.[26] Topical 
immunotherapy offers long-term therapeutic hope for patients with this distressing condition. 
At present, DPCP is considered to be an effective and safe therapeutic method for AA, more 
precisely for severe cases of AA with a relatively low rate of adverse-effects.[18-23] The 
effectiveness of topical immunotherapy with AA has been demonstrated in several reports, 
although the response rate varied greatly from 5% to 85%.[14-15, 18-23] The discrepancy of 
response rates may be due to the type and severity of the AA, the number of patients in the 
clinical study, and different methods of assessing clinical efficacy.  
In this study, we present our experience from the use of DPCP in the treatment of 
patients with severe AA in China. The response rate to DPCP with satisfactory hair regrowth 
was around 56%; in concordance with other previous studies using similar inclusion criteria 
and efficacy evaluation methodology.[18-23] The most common iatrogenic effect is local 
contact dermatitis.[18-23] Certain clinical features, such as history of atopy and autoimmune 
diseases, duration of AA, nail involvement, thyroid antibodies, etc., have been associated with 
AA disease severity in previous studies,[27-28] but were not observed in our patients. The only 
variable significantly correlated with the prognosis was the hair loss area extent of AA.  
Pre-treatment serum IgE levels were significantly higher in the withdrawal due to 
severe side-effects group than in the responders group and non-responders group. Therefore, 
serum IgE level could be used as a prognostic marker to indicate DPCP intolerance. The well-
documented high relapse rate reported in previous medical literature was also observed in our 
patients (40.6%). However, continuous treatment for maintenance of hair growth is generally 
recommended and still effective for patients with relapse.[25,29] Similarly, our relapsed cases 
that continued or restarted on DPCP therapy achieved excellent responses again.  
It is generally accepted that AA is a T lymphocyte mediated inflammatory disease on a 
multigene background, likely triggered by external factors.[1-6] Remission in AA occurs with a 
decrease in Th1 cytokines and relative increase in Th2 cytokines which prompts or enables 
anagen, clinically perceived as hair regrowth.[1-3,9,30-35] In our study, prior to treatment, in all 
AA patients as a group, serum levels of Th1 type cytokines IFN-γ and IL-12 were higher, 
while the Th2 type cytokine IL-5 was lower. These results support the notion of Th1 
prevalence in the etiopathogenesis of AA.  
The exact mechanism of action of the immune-modulating effect in DPCP is unclear, 
but to date it is generally assumed that it acts on different pathways to inhibit inflammation in 
alopecic areas which is achieved mainly by suppression of inflammatory cells, such as CD4+ 
and CD8+ T cells, restoration of equilibrium between Th1 and Th2 responses, or involvement 
of regulatory T cells.[36-42] In our study, post-treatment levels of serum Th1 type cytokines 
IFN-γ and IL-12 were significantly decreased, and levels of serum Th2 type cytokines IL-4 
and IL-10 were increased in the responder group, which was different from the non-responder 
group. Thus, AA patients with a predominant Th1 profile are good candidates for DPCP 
treatment, using IL-12 as an indicator, as it was higher in responders than in non-responders 
prior to treatment. The new cytokine milieu in response to DPCP treatment is likely crucial in 
promoting or enabling entry of hair follicles into an anagen stage leading to hair regrowth. 
However, any further change in the new cytokine balance can also induce the relapse of hair 
loss.  
In contrast, in the DPCP non-responder group, both Th1 and Th2 cytokines were 
higher than that of normal controls prior to DPCP treatment. Most notably, the serum IL-4 
level was 3 fold higher than that observed in both controls and responders before DPCP 
treatment. IL-4 also remained high after the failed treatment, suggesting a persistent 
enhancement of Th2 activity. Moreover, non-responders had no significant decrease in IFN-γ 
serum levels, an increase of IL-12, and a lower level of IL-10 after DPCP treatment indicating 
a failure to inhibit Th1 activity.  
Therefore, a pre-existing high Th2 cytokine profile can apparently counteract the 
therapeutic immune response elicited by DPCP treatment, perhaps resulting in failure to 
inhibit the pathogenic Th1 cytokine activity underlying AA. Thus, elevated pre-treatment 
serum IL-4 levels in AA patients could be used as a negative prognostic marker of DPCP 
therapeutic efficacy. The data indicate AA patients with a high Th2 cytokine profile are not 
good candidates for DPCP treatment, even with a coexisting high Th1 cytokine profile. The 
functional significance of elevated IL-4 in AA is unclear, but it suggests there is also a role for 
Th2 type cytokines in AA pathogenesis in at least some patients, as indicated by other 
research.[42] Increased serum IL-5 and IL-17 levels were also found both in responder and 
non-responder groups after treatment when compared to pre-treatment levels, as well as to 
controls; possibly a response caused by the DPCP induced contact dermatitis. Their role in 
modulating the pathogenic Th1 activity of AA is unclear. 
           In conclusion, the response rate to DPCP of Chinese patients with AA was similar to 
other previous studies involving other ethnic groups and correlated negatively with extent of 
hair loss. Elevated pre-treatment serum total IgE levels can be used as a predictor of DPCP 
intolerance and elevated pre-treatment serum levels of IL-4 and IL-12 can be used as 
unfavorable and favorable predictors of response to DPCP treatment, respectively. Taken 
together, this study provides evidence that the mode of DPCP action may restore of the 
immunological balance by counteracting the pathogenic dominant Th1 reaction of AA. 
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Figures  
 
Figure 1. Serum cytokine profiles of all AA patients 
Serum cytokine profiles of all AA patients pre- and post-topical immunotherapy (A), and as 
compared to healthy controls. AA patients are evaluated separately as responders to DPCP (B) 
and non-responders to DPCP (C) (unit: pg/ml, *P<0.05, **P<0.01). 
Figure 2. Serum cytokine profiles of AA patients in DPCP responders and non-
responders  
Serum cytokine profiles of AA patients in the responder group compared to the non-responder 
group and healthy controls prior to treatment (A) and post-treatment (B) (unit: pg/ml, *P<0.05, 
**P<0.01). 
 
 
 
 
 
Tables 
 
Table 1. Clinical and laboratory data in four treatment groups 
Groups 
Patients’ 
age 
(years) 
Duration 
of 
disease 
(years) 
Hair loss area 
Family 
history of 
AA 
Atopic 
history 
TG-AB  
increase 
TPO-AB    
increase 
EO# 
increase 
EO% 
increase 
ANA 
increase 
 
IgE 
increase 
 
Responder 
group 
28.3± 
11.5 
6.4± 1.2 76.4%±27.1% 
4/32 
(12.5%) 
3/32 
(9.4%) 
9/32 
(28.1%) 
2/32 
(6.3%) 
1/32 
(3.1%) 
3/32 
(9.4%) 
4/32 
(12.5%) 
5/32 
(15.6%) 
Non-
responder 
group 
25.8± 
11.7 
5.7± 4.1 90.0%±19.8% 
3/25 
12.0%) 
3/25 
(12.0%) 
4/25 
(16.0%) 
3/25 
(12.0%) 
1/25 
(4.0%) 
2/25 
(8.0%) 
1/25 
4.0%) 
4/25 
(16%) 
Severe 
side-effect 
group 
27.0± 
16.8 
8.3± 5.2 82.9%±24.3% 0/7 
1/7 
(14.3%) 
0/7 0/7 0/7 0/7 0/7 
5/7 
(71.4%)* 
Voluntary 
withdrawal 
group 
27.0± 
15.0 
4.8± 4.7 81.8%±26.4% 
2/20 
10.0%) 
3/20 
(15.0%) 
4/20 
(20.0%) 
4/20 
(20.0%) 
0/20 
2/20 
(10.0%) 
3/20 
(15.0%) 
5/20 
(25.0%) 
P  value 0.903 0.494 0.066 
0.628 
(χ2=1.74) 
0.937 
(χ2=0.42) 
0.204 
(χ2=4.60) 
0.275 
(χ2=3.88) 
0.658 
(χ2=1.61) 
0.721 
(χ2=1.33) 
0.332 
(χ2=3.42) 
0.026 
(χ2=9.23) 
 
 
 
  
 
 
 
 
 
Table 2. Dermoscopic features in four treatment groups 
Groups Yellow dots Broken hairs Black dots Exclamation mark hairs 
Responder group 14/22 (63.6%) 17/22 (77.3%) 14/22 (63.3%) 9/22 (40.9%) 
Non-responder group 9/17 (52.9%) 7/17 (41.2%) 9/17 (52.9%) 2/17 (11.8%) 
Severe side-effect group 0/2 2/2 (100%) 2/2 (100%) 1/2 (50.0%) 
Voluntary withdrawal group 4/9 (44.4%) 5/9 (55.6%) 6/9 (66.7%) 3/9 (33.3%) 
P value 0.339（χ2=3.168） 0.060（χ2=7.424） 0.678（χ2=1.602） 0.156（χ2=4.843） 
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Figure 1. Global scalp views in four cases pre- and post-treatment 
 
Cases 1 to 3 were in the responder group (case 1 and 2: Grade IV, case 3: Grade III), whereas 
case 4 was in the non-responder group. Global scalp views in four cases are shown before 
treatment, after 2 months treatment (case 2 for the left half scalp, other cases for the right half 
scalp), after 4 months treatment (case 2 on the left half scalp for 4 months and the right half 
scalp for 2 months; case 1 and 3 on the right half scalp for 4 months and the left half scalp for 
2 months; case 4 on the right half scalp for 4 months), and after 6 months treatment. 
 
Figure 2. Scalp dermoscopy of AA 
 
Scalp dermoscopy before treatment (A), after three (B), eight (C), and fourteen (D) weeks of 
DPCP treatment in the same case. 
 
 
